drugset / Trial / NCT03606642
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
Phase 2
Terminated
50 enrolled
HonorHealth Research Institute
Boston Scientific Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding (HBR).
Timeline
- Start
- 2018-11-19
- Primary completion
- 2021-12-31
- Completion
- 2022-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | — |
| Subject | Clopidogrel | Small molecule | 75 mg | Oral |
| Subject | Prasugrel | Small molecule | 10 mg | Oral |
| Subject | Ticagrelor | Small molecule | 90 mg | Oral |